Related Experiment Videos
Second-generation lymphocyte function-associated antigen-1 inhibitors: 1H-imidazo[1,2-alpha]imidazol-2-one
Jiang-Ping Wu1, Jonathan Emeigh, Donghong A Gao
1Research and Development, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, Ridgefield, Connecticut 06877, USA. jwu@rdg.boehringer-ingelheim.com
Journal of Medicinal Chemistry
|October 16, 2004
Summary
Researchers developed novel lymphocyte function-associated antigen-1 (LFA-1) inhibitors with an imidazole-based bicyclic scaffold. These compounds show improved potency, offering new therapeutic potential for LFA-1 mediated conditions.
Area of Science:
- Medicinal Chemistry
- Immunology
- Drug Discovery
Background:
- Lymphocyte function-associated antigen-1 (LFA-1) is a key immune cell adhesion molecule.
- Existing LFA-1 inhibitors, such as hydantoin-based compound BIRT377, have limitations in physicochemical and metabolic properties.
- There is a need for novel LFA-1 inhibitors with improved characteristics.
Purpose of the Study:
- To discover and characterize a new class of LFA-1 inhibitors.
- To optimize LFA-1 inhibitor properties through scaffold modification.
- To explore structure-activity relationships for enhanced potency.
Main Methods:
- Design and synthesis of novel imidazole-based 5,5-bicyclic compounds.
- Structure-activity relationship (SAR) studies to identify key pharmacophores.
- X-ray crystallography to elucidate binding modes within the LFA-1 I-domain.
Main Results:
- A novel 1,3,3-trisubstituted 1H-imidazo[1,2-alpha]imidazol-2-one scaffold was identified.
- Electron-withdrawing groups at C5 and oxygen-containing functional groups on C5-sulfonyl/sulfonamide moieties significantly enhanced potency.
- X-ray data confirmed binding to the LFA-1 I-domain, similar to previously reported inhibitors.
Conclusions:
- The novel imidazole-based bicyclic scaffold represents a promising new class of LFA-1 inhibitors.
- Specific functional group modifications can substantially improve inhibitor potency.
- These findings provide a foundation for developing advanced LFA-1 targeted therapeutics.